Cargando…
Aurora A kinase inhibition compromises its antitumor efficacy by elevating PD-L1 expression
Aurora A plays a critical role in G(2)/M transition and mitosis, making it an attractive target for cancer treatment. Aurora A inhibitors showed remarkable antitumor effects in preclinical studies, but unsatisfactory outcomes in clinical trials have greatly limited their development. In this study,...
Autores principales: | Wang, Xiaobo, Huang, Jing, Liu, Fenglin, Yu, Qian, Wang, Ruina, Wang, Jiaqi, Zhu, Zewen, Yu, Juan, Hou, Jun, Shim, Joong Sup, Jiang, Wei, Li, Zengxia, Zhang, Yuanyuan, Dang, Yongjun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145933/ https://www.ncbi.nlm.nih.gov/pubmed/36928177 http://dx.doi.org/10.1172/JCI161929 |
Ejemplares similares
-
L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression
por: Huang, Jing, et al.
Publicado: (2022) -
Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases
por: Liu, Wang, et al.
Publicado: (2016) -
Aurora kinase A, a synthetic lethal target for precision cancer medicine
por: Mou, Pui Kei, et al.
Publicado: (2021) -
Antitumor profiles and cardiac electrophysiological effects of aurora kinase inhibitor ZM447439
por: Lee, Hyang-Ae, et al.
Publicado: (2019) -
Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy
por: Yue, Chunyan, et al.
Publicado: (2018)